Advertisement

Topics

[Comment] Brentuximab vedotin for advanced Hodgkin's lymphoma

23:29 EST 10 Nov 2017 | The Lancet

Brentuximab vedotin—through CD30-targeted delivery of monomethyl auristatin E into Hodgkin Reed-Sternberg cells—has transformed the management of patients with classical Hodgkin's lymphoma, through both its high frequency and long duration of complete remission.1 Since the initial approval of this agent, there has been high interest in its successful integration into earlier lines of management.2–4

Original Article: [Comment] Brentuximab vedotin for advanced Hodgkin's lymphoma

NEXT ARTICLE

More From BioPortfolio on "[Comment] Brentuximab vedotin for advanced Hodgkin's lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement